Merck & Co., Inc. $MRK Position Cut by Canandaigua National Bank & Trust Co.

Canandaigua National Bank & Trust Co. decreased its position in shares of Merck & Co., Inc. (NYSE:MRK) by 16.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,117 shares of the company’s stock after selling 13,736 shares during the period. Merck & Co., Inc. accounts for approximately 0.9% of Canandaigua National Bank & Trust Co.’s portfolio, making the stock its 23rd biggest holding. Canandaigua National Bank & Trust Co.’s holdings in Merck & Co., Inc. were worth $10,189,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cardano Risk Management B.V. purchased a new stake in Merck & Co., Inc. in the 4th quarter valued at $1,012,530,000. Dimensional Fund Advisors LP grew its position in Merck & Co., Inc. by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. Bank of America Corp DE grew its position in Merck & Co., Inc. by 10.5% during the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Corient Private Wealth LLC increased its stake in Merck & Co., Inc. by 114.7% in the fourth quarter. Corient Private Wealth LLC now owns 5,210,548 shares of the company’s stock valued at $548,462,000 after purchasing an additional 2,783,482 shares during the period. Finally, Employees Provident Fund Board acquired a new position in Merck & Co., Inc. in the fourth quarter valued at $254,206,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Maraldo sold 18,706 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 in the last three months. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Stock Performance

NYSE MRK traded up $0.72 during trading hours on Wednesday, hitting $142.66. 6,349,422 shares of the stock were exchanged, compared to its average volume of 10,674,509. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The company has a market cap of $351.96 billion, a price-to-earnings ratio of 114.12, a price-to-earnings-growth ratio of 6.08 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The stock has a 50-day moving average of $143.10 and a 200 day moving average of $127.76.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts forecast that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Wall Street Analyst Weigh In

MRK has been the subject of several recent research reports. Morgan Stanley decreased their target price on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday. Sanford C. Bernstein boosted their price target on Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research report on Tuesday, August 4th. CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on Merck & Co., Inc. from $150.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday. Finally, Scotiabank boosted their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a report on Tuesday, September 29th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average target price of $148.80.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Morgan Stanley maintained an “overweight” rating on Merck while trimming its price target from $179 to $177, still implying substantial upside. The rating reflects confidence in Keytruda, Merck’s broader product portfolio and its longer-term outlook. Morgan Stanley price target update
• Positive Sentiment: Recent commentary argues that Merck’s pullback over the past month may represent a buying opportunity. Keytruda remains the primary growth driver, while newer products and pipeline assets could help support growth after 2028. Merck stock valuation and outlook
• Neutral Sentiment: Sell-side analysts collectively rate Merck & Co. (MRK) a “moderate buy,” indicating generally favorable sentiment but not unanimous conviction. Merck analyst rating
• Negative Sentiment: A Dutch court ruled for Halozyme Therapeutics in a patent dispute, barring Merck from selling subcutaneous Keytruda in eight European markets. The injunction threatens the rollout of a potentially more convenient version of Merck’s largest drug and could delay related revenue opportunities in Europe. Merck injectable Keytruda European injunction

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.